PCRX Shareholders will receive only $36.50 in cash per share, corresponding to a total equity value of $1.65 billion; Ademi LLP is investigating the transaction price, the benefits obtained by insiders of the company, and the restrictions on competitive bids.

Milwaukee, October 8, 2026 / PRNewswire / -- Ademi LLP indicates that an investigation is underway to determine whether the transaction in which Viatris intends to acquire Pacira (Nasdaq ticker: PCRX) provides fair value to the public shareholders of Pacira, and whether the board of directors of Pacira adequately protected the interests of shareholders during the negotiation and approval of the transaction.

Are you a shareholder of PCRX?

If you hold Pacira shares, Ademi LLP would like to hear your views on this proposed acquisition and your rights as a shareholder.

You can also contact Guri Ademi via email at [email protected], or call the toll-free number 866-264-3995. There are no costs or obligations associated with this for you.

Ademi LLP is investigating what?

• The exchange ratio, and whether it fully reflects the value and future prospects of Pacira.
• Significant control rights changes that are related to transactions and can be obtained by insiders of Pacira;
• Restrictions on competitive bidding, including high termination fees that may deter other potential buyers from making better offers;
• The behavior of the board of directors in negotiating and approving the transaction, as well as whether the board of directors has fulfilled its duties to the public shareholders.

PCRX What should shareholders do?

Contact Ademi LLP to discuss your rights and the investigation regarding them. There are no costs or obligations associated with this for you.

Guri Ademi

About Ademi LLP

Ademi LLP represents investors in handling shareholder litigation involving mergers and acquisitions, privatizations, and the rights of individual shareholders.

Lawyer advertisement. Past results do not guarantee similar outcomes in the future.